Liberty Analytics Co. Initiates Independent Research Coverage on Strategic Diagnostics Inc.

Liberty Analytics Co. Initiates Independent Research Coverage on Strategic
Diagnostics Inc.

CALGARY, Alberta, May 20, 2010 (GLOBE NEWSWIRE) -- Liberty Analytics Co., a
leading provider of large, small- and micro-cap independent investment
research, today initiated coverage on Strategic Diagnostics Inc.
(Nasdaq:SDIX). Liberty Analytics is currently offering a complimentary trial
subscription. To view our research, go to:

About LAC:

Liberty Analytics Co. is a leading provider of independent investment research
in North America. Our services include research analysis on the large, small-
and micro-cap markets, real-time news and financial data, market commentary
and the LAC newsletter. Liberty Analytics' staff of large and small-cap
investment professionals is dedicated to providing the market's investment
community with the tools and avenues necessary to make the important
investment decisions. To view our research reports on a complimentary trial
basis and take advantage of our other services, go to and click on the complimentary trial subscription
button on our home page, or go directly to our registration page at

About Strategic Diagnostics Inc. (Nasdaq:SDIX):

Strategic Diagnostics Inc. (Nasdaq:SDIX) is a biotechnology company that
develops, manufactures and markets antibody products and analytical test kits
for a range of food, water, agricultural, industrial, environmental and
scientific applications.

LAC Disclosure: is not a registered investment advisor and nothing
contained in any materials should be construed as a recommendation to buy or
sell any securities. Liberty Analytics has not been compensated by any of the
above-mentioned companies. Please read our report and visit our Web site,, for complete risks and disclosures.

CONTACT:  Liberty Analytics
          Kevin Mix

Press spacebar to pause and continue. Press esc to stop.